Published Data, Stock Price Movements, and FDA Approvals - Research Report on Johnson & Johnson, Ariad Pharmaceuticals,

Published Data, Stock Price Movements, and FDA Approvals - Research Report on
    Johnson & Johnson, Ariad Pharmaceuticals, PerkinElmer, BD, and Sanofi

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 13, 2013

NEW YORK, December 13, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), PerkinElmer,
Inc. (NYSE: PKI), Becton, Dickinson and Co. (NYSE: BDX), and Sanofi SA (ADR)
(NYSE: SNY). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & JohnsonResearch Report

On December 9, 2013, Janssen Research & Development LLC (Janssen), part of
Janssen Pharmaceutical Companies of Johnson & Johnson (Johnson & Johnson),
announced data from a study published in The Lancet Oncology, evaluating the
safety and activity of ibrutinib as a single-agent therapy in patients over
the age of 65 with previously untreated chronic lymphocytic leukemia (CLL,
N=29) or small lymphocytic lymphoma (SLL, N=2). According to Janssen, the
study achieved its primary endpoint of safety, with data demonstrating
treatment with ibrutinib as an initial therapy was associated with adverse
events (AEs) that were predominantly Grade 1 or 2 in nature. Janssen further
revealed that efficacy data demonstrates that 71% (95% CI, 52.0-85.8) of
patients treated with ibrutinib achieved an objective response (defined as
complete or partial response). Janssen also concluded that it is estimated
that more than 95% of patients would be alive and progression-free at two
years, though estimates of progression-free survival (PFS) and overall
survival (OS) were not reached at the median follow up of 22.1 months. The
Full Research Report on Johnson & Johnson - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Ariad Pharmaceuticals, Inc.Research Report

On December 10, 2013, Ariad Pharmaceuticals, Inc.'s (Ariad Pharmaceuticals)
stock rose 3.50%, ending the day at $4.44. Over the previous three trading
sessions, shares of Ariad Pharmaceuticals declined 2.84% compared to the
Nasdaq Composite which gained 0.68% during the same period. The Full Research
Report on Ariad Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

--

PerkinElmer, Inc.Research Report

On December 10, 2013, PerkinElmer, Inc.'s (PerkinElmer) stock rose 2.38%,
ending the day at $39.61. Over the previous three trading sessions, shares of
PerkinElmer gained 5.54% compared to the S&P 500 which gained 0.99% during the
same period. The Full Research Report on PerkinElmer, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/2016_PKI

--

Becton, Dickinson and Co.Research Report

On December 3, 2013, BD Diagnostics, a segment of Becton, Dickinson and Co.
(BD), announced that it has received FDA clearance to market the BD MAX
StaphSR Assay for use on the fully-automated BD MAX System. BD Diagnostics
reported that the assay, when used with eXTended Detection Technology, detects
Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus
(MRSA) DNA directly from nasal swabs, including mecA dropout mutants and new
strains of MRSA that may not be detected by other assays. Dr. Tobi Karchmer,
Worldwide Vice President, Medical Affairs, BD Diagnostics, said, "Increased
accuracy in determining patient colonization with either S. aureus or MRSA can
enable clinicians to implement appropriate pre-surgical prophylaxis and direct
appropriate utilization of isolation and decolonization." Dr. Karchmer added,
"With results available in approximately two hours compared to two or more
days for culture methods, the BD MAX StaphSR Assay provides accurate and
timely information to help physicians ensure safe and appropriate management
of surgical patients." The Full Research Report on Becton, Dickinson and Co. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0175_BDX

--

Sanofi SA (ADR)Research Report

On December 5, 2013, Sanofi SA (ADR) (Sanofi) announced the results of a
24-week Phase IIIb clinical study showing that Lyxumia (lixisenatide) met the
primary endpoint of non-inferiority in blood sugar lowering (HbA[1c]) when
administered either before breakfast or the main meal of the day. According to
Sanofi, these results indicate that lixisenatide can effectively lower blood
sugar at either time of administration. According to Sanofi, the results
showed that a comparable reduction in body weight, regardless of the meal
before which lixisenatide was administered, was achieved. Lastly, Sanofi
informed that gastrointestinal tolerability was comparable regardless of time
administration, with no cases of severe hypoglycemia in either arm. The Full
Research Report on Sanofi SA (ADR) - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/29ea_SNY

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.